XAIR

Beyond Air Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$6.33M
P/E Ratio
EPS
$-3.97
Beta
0.22
52W High
$4.78
52W Low
$0.34
50-Day MA
$0.46
200-Day MA
$1.12
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Beyond Air Inc

Beyond Air, Inc., a clinical-stage biopharmaceutical and medical device company, develops nitric oxide (NO) generators and delivery systems. The company is headquartered in Garden City, New York.

Official WebsiteUSAFY End: March

Fundamentals

Revenue (TTM)$7.68M
Gross Profit (TTM)252,000
EBITDA$-25.79M
Operating Margin-376.00%
Return on Equity-334.10%
Return on Assets-55.50%
Revenue/Share (TTM)$0.93
Book Value$0.96
Price-to-Book1.08
Price-to-Sales (TTM)0.82
EV/Revenue2.394
EV/EBITDA-4.23
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)65.50%
Shares Outstanding$14.41M
Float$14.12M
% Insiders2.14%
% Institutions9.66%

Historical Volatility

HV 10-Day
61.28%
HV 20-Day
90.12%
HV 30-Day
87.09%
HV 60-Day
113.66%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($8.00 target)
1
Strong Buy
1
Buy
1
Hold

Latest News

Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day.

GlobeNewsWire6/22/2026Neutral
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026.

GlobeNewsWire6/1/2026Neutral
Beyond Air to Participate in the D. Boral Capital Global Conference 2026

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.

GlobeNewsWire4/15/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026